ECSP972201A - FUSION POLYPEPTIDES - Google Patents

FUSION POLYPEPTIDES

Info

Publication number
ECSP972201A
ECSP972201A ECSP972201A ECSP972201A EC SP972201 A ECSP972201 A EC SP972201A EC SP972201 A ECSP972201 A EC SP972201A EC SP972201 A ECSP972201 A EC SP972201A
Authority
EC
Ecuador
Prior art keywords
fusion polypeptides
preparation
intermediates
fused
polypeptides
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Hermann Gram
Philip Lake
Mary Ellen Digan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP972201 priority Critical patent/ECSP972201A/en
Publication of ECSP972201A publication Critical patent/ECSP972201A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los polipéptidos de fusión y sales del mismo que comprenden al menos un dominio de unión de IgE fusionado al menos un componente de seroalbúmina humana, opcionalmente vía un enlazante peptídico, y en particular polipéptidos de fusión diméricos que comprenden proteína HSA fusionada, en cada uno de sus amino y carboxi terminales, a un dominio extracelular de la cadena alfa del receptor de alta afinidad humano para la IgE (FeERIalfa); los procesos para la preparación de los mismos, los polipéptidos funcionalmente equivalentes que son intermediarios en su preparación, y los intermedios polipéptidos y oligonucleotidicos y vectores de los mismos. Ellos están indicados para usarse en la prevención y/o tratamiento de enfermedades alérgicas medianas por la IgR y padecimientos relacionados tales como la dermatitis atópica, asma atópica y curticaria crónica.Fusion polypeptides and salts thereof comprising at least one IgE binding domain fused to at least one component of human serum albumin, optionally via a peptide linker, and in particular dimeric fusion polypeptides comprising fused HSA protein, in each of its amino and carboxy termini, to an extracellular domain of the human IgE high affinity receptor alpha chain (FeERIalfa); the processes for the preparation thereof, the functionally equivalent polypeptides that are intermediates in their preparation, and the polypeptide and oligonucleotide intermediates and vectors thereof. They are indicated for use in the prevention and / or treatment of medium allergic IgR diseases and related conditions such as atopic dermatitis, atopic asthma and chronic curticaria.

ECSP972201 1997-07-25 1997-07-25 FUSION POLYPEPTIDES ECSP972201A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP972201 ECSP972201A (en) 1997-07-25 1997-07-25 FUSION POLYPEPTIDES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP972201 ECSP972201A (en) 1997-07-25 1997-07-25 FUSION POLYPEPTIDES

Publications (1)

Publication Number Publication Date
ECSP972201A true ECSP972201A (en) 1999-01-19

Family

ID=42043032

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP972201 ECSP972201A (en) 1997-07-25 1997-07-25 FUSION POLYPEPTIDES

Country Status (1)

Country Link
EC (1) ECSP972201A (en)

Similar Documents

Publication Publication Date Title
AR008077A1 (en) A FUSION POLYPEPTIDE OR A SALT OF THE SAME, ITS USE, A PROCESS TO PREPARE THEM, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND A VECTOR.
AR119235A1 (en) FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
Hempstead Dissecting the diverse actions of pro-and mature neurotrophins
AR039231A1 (en) NEW OX40R UNION AGENTS
BR9806954A (en) Tumor necrosis factor 6a and 6b receptors
PE20190352A1 (en) GDF 15 FUSION PROTEINS AND USES OF THEM
NO20000934L (en) Adipocyte-specific protein homologs
HRP20130194T1 (en) Immunosuppressive polypeptides and nucleic acids
DK25489A (en) PROCEDURE FOR PREPARING A SECURED HUMAN-PDGF RECEPTOR ANALOGUE, A SECURED BIOLOGICAL ACTIVE PEPTID DIMER UNDER A SECERED LANDAND-BINDING RECEPTOR ANALOGUE AND PHARMACEUTICAL COMPOSITION COMPOSITION
ATE259419T1 (en) HUMAN CYR61, AN EXTRACELLULAR MATRIX SIGNALING MOLECULE
BRPI0407293A (en) T cell lasting response
DE60033293D1 (en) NEW B7-4 MOLECULES AND THEIR USES
MX2009013955A (en) Bone morphogenetic protein (bmp)-binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and use of same.
ATE335818T1 (en) LIGAND POLYPEPTIDES FOR HYPOPHYSIS G-PROTEIN COUPLED RECEPTOR PROTEIN, THEIR PRODUCTION AND APPLICATION
ATE327328T1 (en) ADIPOCYTE-SPECIFIC PROTEIN HOMOLOGUE
DE69836963D1 (en) PGC-1, A NOVEL PPAR-GRAY CO-ACTIVATOR FROM BROWN FAT FABRIC
MX2025010859A (en) Dap10/dap12 fusion polypeptides
Lecrone et al. Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins
DE69842225D1 (en) A composition comprising an antibody that selectively binds to a cysteine-rich secreted protein (CRSP)
Weston et al. Identification of integrin alpha 2 beta 1 as cell surface receptor for the carboxyl-terminal propeptide of type I procollagen.
BR9709900A (en) Protein binding proteins of prions and their uses.
ECSP972201A (en) FUSION POLYPEPTIDES
WO2003083078A3 (en) Novel human cell surface protein with immunoglobulin folds, bgs-19
Choi et al. Neuroprotective function of thymosin-β and its derivative peptides on the programmed cell death of chick and rat neurons
BR0010479A (en) Prp type gene